184 related articles for article (PubMed ID: 32592387)
21. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137.
Amoureux L; Sauge J; Sarret B; Lhoumeau M; Bajard A; Tetu J; Bador J; Neuwirth C;
J Cyst Fibros; 2019 Nov; 18(6):804-807. PubMed ID: 31104975
[TBL] [Abstract][Full Text] [Related]
22. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.
Lambiase A; Catania MR; Del Pezzo M; Rossano F; Terlizzi V; Sepe A; Raia V
Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):973-80. PubMed ID: 21279730
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic and molecular characterisations of carbapenem-resistant
Simo Tchuinte PL; Rabenandrasana MAN; Kowalewicz C; Andrianoelina VH; Rakotondrasoa A; Andrianirina ZZ; Enouf V; Ratsima EH; Randrianirina F; Collard JM
Antimicrob Resist Infect Control; 2019; 8():31. PubMed ID: 30792853
[TBL] [Abstract][Full Text] [Related]
24. Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans.
Spierer O; Monsalve PF; OʼBrien TP; Alfonso EC; Gologorsky D; Miller D
Cornea; 2016 May; 35(5):626-30. PubMed ID: 26989957
[TBL] [Abstract][Full Text] [Related]
25. Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens.
Traglia G; Papalia M; Almuzara M; Gutkind G; Centrón D; Vay C; Radice M; Ramírez MS
Curr Microbiol; 2014 Oct; 69(4):501-6. PubMed ID: 24894902
[TBL] [Abstract][Full Text] [Related]
26. Complicated intra-abdominal infection caused by extended drug-resistant Achromobacter xylosoxidans.
Teng SO; Ou TY; Hsieh YC; Lee WC; Lin YC; Lee WS
J Microbiol Immunol Infect; 2009 Apr; 42(2):176-80. PubMed ID: 19597652
[TBL] [Abstract][Full Text] [Related]
27. Accumulation of Antibiotic Resistance Genes in Carbapenem-Resistant
Douraghi M; Kenyon JJ; Aris P; Asadian M; Ghourchian S; Hamidian M
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269158
[TBL] [Abstract][Full Text] [Related]
28. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.
Van Daele S; Verhelst R; Claeys G; Verschraegen G; Franckx H; Van Simaey L; de Ganck C; De Baets F; Vaneechoutte M
J Clin Microbiol; 2005 Jun; 43(6):2998-3002. PubMed ID: 15956444
[TBL] [Abstract][Full Text] [Related]
29. Multi-locus sequence analysis for identification of Achromobacter xylosoxidans from blood culture.
Takei T; Konuma T; Takahashi S; Miharu Y; Suzuki M; Shibata H; Ishii H; Kato S; Takahashi S; Tojo A
Infect Dis (Lond); 2016; 48(11-12):864-6. PubMed ID: 27376508
[No Abstract] [Full Text] [Related]
30. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
Lobo LJ; Tulu Z; Aris RM; Noone PG
Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
[TBL] [Abstract][Full Text] [Related]
31. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.
Raso T; Bianco O; Grosso B; Zucca M; Savoia D
APMIS; 2008 Sep; 116(9):837-41. PubMed ID: 19024606
[TBL] [Abstract][Full Text] [Related]
32. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.
Magni A; Trancassini M; Varesi P; Iebba V; Curci A; Pecoraro C; Cimino G; Schippa S; Quattrucci S
J Clin Microbiol; 2010 Apr; 48(4):1035-9. PubMed ID: 20107101
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
34. Hospital-acquired pneumonia due to Achromobacter xylosoxidans in the elderly: A single-center retrospective study in Beijing.
Liu C; Guo J; Yan W; Jin Y; Pan F; Fang X; Qin L; Liu C
J Infect Dev Ctries; 2017 Jan; 11(1):10-18. PubMed ID: 28141585
[TBL] [Abstract][Full Text] [Related]
35. A novel family of genomic resistance islands, AbGRI2, contributing to aminoglycoside resistance in Acinetobacter baumannii isolates belonging to global clone 2.
Nigro SJ; Farrugia DN; Paulsen IT; Hall RM
J Antimicrob Chemother; 2013 Mar; 68(3):554-7. PubMed ID: 23169892
[TBL] [Abstract][Full Text] [Related]
36. In vitro synergistic activity of combined piperacillin and tobramycin against clinical strains of Achromobacter xylosoxidans.
Duez JM; Hadjait-Savioz M; Siebor E; Astruc K; Bador J; Péchinot A; Sixt N; Huet F; Neuwirth C
J Chemother; 2010 Apr; 22(2):139-41. PubMed ID: 20435577
[No Abstract] [Full Text] [Related]
37. Prevalence and Characterization of Integrons in Multidrug Resistant Acinetobacter baumannii in Eastern China: A Multiple-Hospital Study.
Chen J; Li H; Yang J; Zhan R; Chen A; Yan Y
Int J Environ Res Public Health; 2015 Aug; 12(8):10093-105. PubMed ID: 26308028
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant
Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816722
[No Abstract] [Full Text] [Related]
39. [Achromobacter xylosoxidans colonisation in bronchiectasis].
Gázquez G
Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):758-9; author reply 759. PubMed ID: 20846757
[No Abstract] [Full Text] [Related]
40. Mediastinitis superinfected by Achromobacter xylosoxidans. A case report.
Marion-Sanchez K; Lion F; Olive C; Cailleaux G; Roques F
J Infect Chemother; 2018 Dec; 24(12):987-989. PubMed ID: 29895453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
